The benefits outweigh the risks: Healthcare analyst on U.S. criticism of AstraZeneca's trial data
Jason Kolbert, director of research at Dawson James Securities, joins BNN Bloomberg for his reaction on AstraZeneca's U.S. trial results potentially being outdated.
